Cargando…

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spoerke, Jill M., Gendreau, Steven, Walter, Kimberly, Qiu, Jiaheng, Wilson, Timothy R., Savage, Heidi, Aimi, Junko, Derynck, Mika K., Chen, Meng, Chan, Iris T., Amler, Lukas C., Hampton, Garret M., Johnston, Stephen, Krop, Ian, Schmid, Peter, Lackner, Mark R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869259/ https://www.ncbi.nlm.nih.gov/pubmed/27174596 http://dx.doi.org/10.1038/ncomms11579

Ejemplares similares

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
por: Chen, Jessica W., et al.
Publicado: (2023)

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
por: Hutchinson, Katherine E., et al.
Publicado: (2023)

Molecular Biomarker Analyses Using Circulating Tumor Cells
por: Punnoose, Elizabeth A., et al.
Publicado: (2010)

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples
por: Wilson, Timothy R., et al.
Publicado: (2014)

A Review of Fulvestrant in Breast Cancer
por: Nathan, Mark R., et al.
Publicado: (2017)

Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer
por: Jacobson, Anne
Publicado: (2022)

Experiments with relativistic exotic nuclei at the ERS - ESR facilities
por: Geissel, H
Publicado: (1996)

ESR/ERS white paper on lung cancer screening
por: Kauczor, Hans-Ulrich, et al.
Publicado: (2015)

ESR/ERS white paper on lung cancer screening
por: Kauczor, Hans-Ulrich, et al.
Publicado: (2015)

Fulvestrant and the sequential endocrine cascade for advanced breast cancer
por: Johnston, S
Publicado: (2004)

Retrospective Evaluation of Fulvestrant Efficacy and Clinical Results in Patients Using Fulvestrant
por: Kut, Engin, et al.
Publicado: (2023)

Economic evaluation of fulvestrant as an extra step in the treatment sequence for ER-positive advanced breast cancer
por: Cameron, D A, et al.
Publicado: (2008)

Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells
por: Traboulsi, Tatiana, et al.
Publicado: (2018)

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2− advanced breast cancer
por: Elias, Anthony D., et al.
Publicado: (2023)

Fulvestrant: pharmacokinetics and pharmacology
por: Robertson, J F R, et al.
Publicado: (2004)

Prevalence of ESR1 Mutation in Chinese ER-Positive Breast Cancer
por: Zhu, Wenzhen, et al.
Publicado: (2020)

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
por: Xu, Tong, et al.
Publicado: (2022)

Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer
por: O’Leary, Ben, et al.
Publicado: (2020)

Unconventional isoquinoline-based SERMs elicit fulvestrant-like transcriptional programs in ER+ breast cancer cells
por: Hancock, G. R., et al.
Publicado: (2022)

Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer: The MANTA Phase 2 Randomized Clinical Trial
por: Schmid, Peter, et al.
Publicado: (2019)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
por: Colombo, Giorgio Lorenzo, et al.
Publicado: (2023)

Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ
por: Mishra, Ameet K., et al.
Publicado: (2016)

Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer
por: Haddad, Tufia C., et al.
Publicado: (2017)

Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patients
por: Liu, Jingyu, et al.
Publicado: (2019)

Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
por: Smyth, Lillian M., et al.
Publicado: (2021)

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents
por: Wang, Guangdi
Publicado: (2020)

The ESR Patient Advisory Group (ESR-PAG)
Publicado: (2015)

ERβ1 Sensitizes and ERβ2 Desensitizes ERα-Positive Breast Cancer Cells to the Inhibitory Effects of Tamoxifen, Fulvestrant and Their Combination with All-Trans Retinoic Acid
por: Meligova, Aggeliki K., et al.
Publicado: (2023)

The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase III adjuvant population
por: Wilson, Timothy R, et al.
Publicado: (2016)

Fulvestrant-induced toxic epidermal necrolysis
por: Morales-Conde, Macarena, et al.
Publicado: (2019)

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance
por: Nardone, Agostina, et al.
Publicado: (2018)

Influence of Estrogen Treatment on ESR1(+) and ESR1(−) Cells in ER(+) Breast Cancer: Insights from Single-Cell Analysis of Patient-Derived Xenograft Models
por: Mori, Hitomi, et al.
Publicado: (2021)

Fulvestrant-induced expression of erbB3 and erbB4 sensitizes ER-positive breast cancer cells to heregulins
por: Hutcheson, IR, et al.
Publicado: (2010)

Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancer
por: Kaminska, Kamila, et al.
Publicado: (2021)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models
por: Hopcroft, Lorna, et al.
Publicado: (2023)

Revisiting Fulvestrant Dosing in Uncertain Economic Times
por: Patel, Amol, et al.
Publicado: (2021)

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers
por: Schleifman, Erica B., et al.
Publicado: (2014)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8o1i72k4v35tgr2d3pss7qo6vm